BioCentury | Jan 21, 2020
Company News

Horizon gains first FDA approval in thyroid eye disease

...cash. Horizon gained Tepezza through its 2017 acquisition of River Vision Development Corp. for $145 million up front. River Vision...
BioCentury | May 11, 2017
Company News

Horizon acquires rare eye disease therapy

...acquired single-asset company River Vision Development Corp. (New York, N.Y.) and its Grave's eye disease candidate teprotumumab (RV001). River Vision...
...insulin-like growth factor-1 (IGF-1) receptor (IGF1R) has breakthrough therapy and Orphan Drug designations from FDA. River Vision...
...Horizon Pharma plc (NASDAQ:HZNP), Dublin, Ireland River Vision Development Corp. , New York, N.Y. Business: Ophthalmic Alicia Parker teprotumumab Horizon Pharma plc River Vision Development Corp. Insulin-like...
BioCentury | May 11, 2017
Clinical News

Teprotumumab meets in Phase II thyroid eye disease trial

...thyroid eye disease, with a BLA submission slated for 2H19. Earlier this month, Horizon acquired River Vision Development Corp....
BioCentury | May 8, 2017
Company News

Horizon acquires rare eye disease therapy

...company River Vision Development Corp. (New York, N.Y.), giving it Graves' eye disease candidate teprotumumab ( RV001 ). River Vision...
...BLA in 2H19 for teprotumumab, which has breakthrough therapy and Orphan Drug designations from FDA. River Vision...
...per share on $248 million. Horizon sank $5.46 (35%) to $10.12 on Monday. Alicia Parker RV001 teprotumumab Horizon Pharma plc River Vision Development Corp. Insulin-like...
BioCentury | Sep 12, 2016
Clinical News

Teprotumumab regulatory update

...targeting the insulin-like growth factor-1 (IGF-1) receptor is in Phase II testing for the indication. River Vision...
...royalties (see BioCentury, Dec. 7, 2009 & June 17, 2013). Genmab A/S (CSE:GEN), Copenhagen, Denmark River Vision Development Corp....
BioCentury | Jun 17, 2013
Clinical News

Teprotumumab regulatory update

...granted Orphan Drug designation to teprotumumab to treat active phase Graves' orbitopathy (thyroid eye disease). River Vision...
...double-blind, placebo-controlled, U.S. Phase II trial in about 84 patients with active thyroid eye disease. River Vision...
...by Narrow River Management L.P. to develop teprotumumab for Graves' orbitopathy and other potential indications. River Vision...
Items per page:
1 - 6 of 6
BioCentury | Jan 21, 2020
Company News

Horizon gains first FDA approval in thyroid eye disease

...cash. Horizon gained Tepezza through its 2017 acquisition of River Vision Development Corp. for $145 million up front. River Vision...
BioCentury | May 11, 2017
Company News

Horizon acquires rare eye disease therapy

...acquired single-asset company River Vision Development Corp. (New York, N.Y.) and its Grave's eye disease candidate teprotumumab (RV001). River Vision...
...insulin-like growth factor-1 (IGF-1) receptor (IGF1R) has breakthrough therapy and Orphan Drug designations from FDA. River Vision...
...Horizon Pharma plc (NASDAQ:HZNP), Dublin, Ireland River Vision Development Corp. , New York, N.Y. Business: Ophthalmic Alicia Parker teprotumumab Horizon Pharma plc River Vision Development Corp. Insulin-like...
BioCentury | May 11, 2017
Clinical News

Teprotumumab meets in Phase II thyroid eye disease trial

...thyroid eye disease, with a BLA submission slated for 2H19. Earlier this month, Horizon acquired River Vision Development Corp....
BioCentury | May 8, 2017
Company News

Horizon acquires rare eye disease therapy

...company River Vision Development Corp. (New York, N.Y.), giving it Graves' eye disease candidate teprotumumab ( RV001 ). River Vision...
...BLA in 2H19 for teprotumumab, which has breakthrough therapy and Orphan Drug designations from FDA. River Vision...
...per share on $248 million. Horizon sank $5.46 (35%) to $10.12 on Monday. Alicia Parker RV001 teprotumumab Horizon Pharma plc River Vision Development Corp. Insulin-like...
BioCentury | Sep 12, 2016
Clinical News

Teprotumumab regulatory update

...targeting the insulin-like growth factor-1 (IGF-1) receptor is in Phase II testing for the indication. River Vision...
...royalties (see BioCentury, Dec. 7, 2009 & June 17, 2013). Genmab A/S (CSE:GEN), Copenhagen, Denmark River Vision Development Corp....
BioCentury | Jun 17, 2013
Clinical News

Teprotumumab regulatory update

...granted Orphan Drug designation to teprotumumab to treat active phase Graves' orbitopathy (thyroid eye disease). River Vision...
...double-blind, placebo-controlled, U.S. Phase II trial in about 84 patients with active thyroid eye disease. River Vision...
...by Narrow River Management L.P. to develop teprotumumab for Graves' orbitopathy and other potential indications. River Vision...
Items per page:
1 - 6 of 6